What Drucker's June 2026 Review Reveals About the Future of GLP-1 Medications

Medicine does not usually change direction overnight. But sometimes a single paper works like a map pointing out that the road is longer than anyone expected. In June 2026, physician Daniel Drucker, one of the most cited researchers in the field of GLP-1 medications worldwide, published a review that is stirring conversations in clinics and research labs alike. The central message: these compounds act on far more organs than the scientific community was betting on five years ago.

Daniel Drucker is a professor at the University of Toronto and spends most of his time studying how GLP-1 drugs interact with the human body. When he publishes something, the field holds its breath. This time, the paper is not only about weight loss. It is about kidneys, liver, and the brain.

GLP-1 and the Kidneys: What the Evidence Shows

The kidneys are one of the most surprising frontiers. Recent clinical trials indicate that people using GLP-1 medications show significant reductions in kidney injury markers. One of them is proteinuria, which means protein is present in urine in abnormal amounts. When the kidneys are working well, they do not let protein slip through into urine. When the renal structure is compromised, that changes.

Data from studies like FLOW, which followed patients with diabetic kidney disease, shows that semaglutide use was associated with a meaningful reduction in the progression of kidney damage. For those living with diabetic nephropathy, this represents a real possibility of postponing dialysis and transplant. Nothing trivial about that.

The connection works in part because GLP-1 drugs seem to improve blood flow within the kidneys and reduce local inflammatory processes. It is as if the medication helps the kidney work with less effort. And less effort means less wear and tear over the years.

For anyone managing a kidney condition related to diabetes, tracking these indicators over time is essential for identifying patterns and bringing detailed information to the nephrologist appointment. Ozempro lets you log test results and notes on how you feel day to day, which is not always top of mind when the appointment is already on the calendar.

GLP-1 and the Liver: Fat, Inflammation, and More

If the kidneys surprised, the liver did not fall behind. Clinical trials show that GLP-1 medications can reduce fat accumulated in the organ by amounts ranging from 20 to 40 percent in certain patient groups. This finding is especially relevant because nonalcoholic fatty liver disease, known by the acronym NAFLD, often goes undetected for years.

In Brazil, it is estimated that about 30 percent of the adult population has some degree of fat in the liver. Most people do not know it. The condition causes no obvious symptoms in the early stage, but it can progress to inflammation, fibrosis, and, in advanced cases, cirrhosis. Once inflammation enters the picture, the situation becomes more serious.

GLP-1 drugs seem to help the liver in more than one way. Besides reducing fat, there is evidence that they lower inflammatory markers in the organ. Think of it as tackling more than one problem at once: less fat means less inflammation, and less inflammation means lower risk of progression to more severe conditions.

This dual effect is what has been drawing hepatologists' attention. NAFLD has already been called "the next epidemic of liver disease" in scientific publications for good reason. If a medication already used for diabetes and obesity can impact this condition, the reach is enormous.

GLP-1 and the Brain: Hunger, Mood, and Cognitive Function

Here we enter territory that still requires careful interpretation, but that deserves attention. GLP-1 receptors are present in brain regions linked to appetite and satiety control. This means that when you use a medication of this type, you are directly interfering with neural circuits that regulate hunger. It is not just a feeling in the stomach. It is an action in the brain.

But the story does not stop at hunger. Recent research points to a possible anti-inflammatory effect of GLP-1 drugs in the central nervous system. Chronic inflammation is associated with several neurodegenerative diseases, including Alzheimer. We do not yet have definitive human data, but the results in experimental models are promising enough that major research centers have begun long-term studies.

What does this mean in practice? That, in the future, GLP-1 medications may eventually be indicated not only for weight control, but also for protecting cognitive function. That would completely change the profile of these drugs in preventive medicine.

For anyone wanting to understand better how appetite control works in practice, you can evaluate your medication use profile and find out whether a GLP-1 might be a suitable tool for your goals by taking the quiz here.

What This Means in Practice

Translating what happens in the lab to the daily life of someone who uses or is considering GLP-1 medications requires clarity. The first thing to understand is that none of these new indications are currently approved in Brazil for the uses I have just described. The difference between scientific evidence and clinical application may seem obvious, but it is easy to forget when the results are so encouraging.

This is not about downplaying the data. They are promising. But the path between what a clinical trial shows and what a doctor can prescribe goes through regulatory approvals. That does not mean you should stand still.

In the coming years, we will likely see more data emerge and, eventually, approvals happen. Until then, the best approach is to stay informed, discuss what you are reading with your doctor, and monitor how your body responds to treatment. This follow-up makes a difference when it comes time to adjust doses, switch medications, or identify effects that deserve attention.

Ozempro works as a routine companion: it lets you log medications, set reminders for injection times, and track side effects, which is especially useful when treatment involves more than one health goal.

When These New Indications Should Reach Brazil

The process for approving new indications by ANVISA is not straightforward. It is not a simple label extension where the company submits a request and that is it. It is a regulatory review that requires evidence and can take 2 to 5 years after the presentation of robust data.

This means the findings described in this article are not yet available for formal medical use in Brazil. But it also means the clock has already started. Patients who follow this research with interest are better prepared to discuss it with their doctors when approvals do come through.

The potential impact on Brazil's public and private healthcare systems is also a question gaining weight. If millions of Brazilians gain access to a medication with effects on kidneys, liver, and brain, the dynamics of chronic disease treatment in the country will shift significantly.

Conclusion: A Chapter That Is Only Just Beginning

Kidneys, liver, and brain. Three organs, three fronts of investigation, all at the same time. Drucker's review did not invent anything, but it organized what we already knew in a way that makes one thing clear: GLP-1 drugs still have a great deal to reveal.

Research in this field is among the most active in the world right now. New findings should emerge over the next few years, and the profile of these medications is likely to become increasingly complex and interesting.

Following all of this with a critical eye is the best way to benefit. This blog will keep tracking every development, always translating science into the language you use in everyday life. Stay around, because there is more to come.